PT-141 code raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-26. Anything still debated is marked as such rather than presented as settled.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
== Books == Interstellar Grains (Chapman & Hall, London, 1967) Light Scattering Functions for Small Particles with Applications in Astronomy (Wiley, New York, 1973) Solid-State Astrophysics (ed. with D.J. Morgan) (D. Reidel, Boston, 1975) Interstellar Matter (with F.D. Khan & P.G. Mezger) (Swiss Society of Astronomy and Astrophysics, 1974) The Cosmic Laboratory (University College of Cardiff, 1975) Lifecloud: The Origin of Life in the Universe (with Fred Hoyle) (J.M. Dent, London, 1978) Diseases from Space (with Fred Hoyle) (J.M. Dent, London, 1979) Origin of Life (with Fred Hoyle) (University College Cardiff Press, 1979) Space Travellers: The Bringers of Life (with Fred Hoyle) (University College Cardiff Press, 1981) Evolution from Space (with Fred Hoyle) (J.M.
===== MeSH D08.811.913.477 – nitrogenous group transferases (EC 2.6) ===== MeSH D08.811.913.477.700 – transaminases MeSH D08.811.913.477.700.100 – alanine transaminase MeSH D08.811.913.477.700.120 – 2-aminoadipate transaminase MeSH D08.811.913.477.700.200 – 4-aminobutyrate transaminase MeSH D08.811.913.477.700.225 – aspartate aminotransferases MeSH D08.811.913.477.700.225.249 – aspartate aminotransferase, cytoplasmic MeSH D08.811.913.477.700.225.500 – aspartate aminotransferase, mitochondrial MeSH D08.811.913.477.700.286 – beta-alanine-pyruvate transaminase MeSH D08.811.913.477.700.347 – d-alanine transaminase MeSH D08.811.913.477.700.470 – Glutamate synthase (ferredoxin) MeSH D08.811.913.477.700.500 – glutamine-fructose-6-phosphate transaminase (isomerizing) MeSH D08.811.913.477.700.525 – glycine transaminase MeSH D08.811.913.477.700.535 – leucine transaminase MeSH D08.811.913.477.700.550 – l-lysine 6-transaminase MeSH D08.811.913.477.700.700 – ornithine-oxo-acid transaminase MeSH D08.811.913.477.700.800 – succinyldiaminopimelate transaminase MeSH D08.811.913.477.700.850 – tryptophan transaminase MeSH D08.811.913.477.700.900 – tyrosine transaminase
==== Other countries ==== The legal status of 1S-LSD outside of Germany is not well-documented. Given its structural similarity to LSD, it may be considered a controlled substance analogue in jurisdictions like the United States, where laws like the Federal Analogue Act could apply. Potential users and researchers should verify the legal status of 1S-LSD in their respective countries before acquisition or use.
The activity of tyrosine hydroxylase in the brains of patients with Alzheimer's disease has been shown to be significantly reduced compared to healthy individuals. Tyrosine hydroxylase is also an autoantigen in autoimmune polyendocrine syndrome (APS) type I. A consistent abnormality in Parkinson's disease is degeneration of dopaminergic neurons in the substantia nigra, leading to a reduction of striatal dopamine levels. As tyrosine hydroxylase catalyzes the formation of L-DOPA, the rate-limiting step in the biosynthesis of dopamine, tyrosine hydroxylase-deficiency does not cause Parkinson's disease, but typically gives rise to infantile parkinsonism, although the spectrum extends to a condition resembling dopamine-responsive dystonia. A direct pathogenetic role of tyrosine hydroxylase has also been suggested, as the enzyme is a source of H2O2 and other reactive oxygen species (ROS), and a target for radical-mediated injury. It has been demonstrated that L-DOPA is effectively oxidized by mammalian tyrosine hydroxylase, possibly contributing to the cytotoxic effects of L-DOPA. Like other cellular proteins, tyrosine hydroxylase is also a possible target for damaging alterations induced by ROS. This suggests that some of the oxidative damage to tyrosine hydroxylase could be generated by the tyrosine hydroxylase system itself. Tyrosine hydroxylase can be inhibited by the drug α-methyl-para-tyrosine (metirosine).
Sources: en.wikipedia.org
Excessive amounts of valproic acid can result in somnolence, tremor, stupor, respiratory depression, coma, metabolic acidosis, and death. In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/L during controlled therapy, but may reach 150–1500 mg/L following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography. In contrast to other antiepileptic drugs, at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate's weak acid property (pKa of 4.9). In severe intoxication, hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body. Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored. Supplemental L-carnitine is indicated in patients having an acute overdose and also prophylactically in high risk patients. Acetyl-L-carnitine lowers hyperammonemia less markedly than L-carnitine.
=== Recognition === Recognition of stop codons in bacteria have been associated with the so-called 'tripeptide anticodon', a highly conserved amino acid motif in RF1 (PxT) and RF2 (SPF). Even though this is supported by structural studies, it was shown that the tripeptide anticodon hypothesis is an oversimplification.
At the Second Africa-South America Summit, held in Venezuela in September 2009, he called for a military alliance across Africa and Latin America to rival NATO. That same month he traveled to New York City and addressed the United Nations General Assembly for the first time on 23 September 2009, using it to condemn "Western aggression", and spoke for just over 90 minutes instead of the allotted 15. In the spring of 2010, Gaddafi proclaimed jihad against Switzerland after Swiss police accused two of his family members of criminal activity in the country, resulting in the breakdown of bilateral relations. Gaddafi allegedly financed Nicolas Sarkozy in the 2007 French presidential election. He also financed Austrian far-right politician Jörg Haider starting in 2000. As revealed by documents found in Moussa Koussa's Tripoli office, the CIA and MI6 both extradited terrorism suspects to Libya from 2002 to 2004, with the CIA having sent suspects for questioning to Libya at least 8 times, despite the nation's reputation for torture. A 2012 Human Rights Watch report conducted interviews with 14 former Libyan detainees, mostly members of the anti-Gaddafi Libyan Islamic Fighting Group, who testified to being tortured at CIA prisons through methods such as waterboarding before their extradition to Libya, followed by torture in Libyan prisons by beating and use of electric shocks.
Sources: en.wikipedia.org
However, unique cultural-specific phenotypes of disordered eating emerged prior to Western influence. For example, restrictive eating patterns were found in Japan as early as the 18th century and fewer reports of eating disorders were found between 1868 and 1944, when rapid Westernization occurred. Sex-specific stressors and cultural dynamics could be implicated in this independent development of anorexia nervosa symptomology.
The 2026 United States House of Representatives elections in Texas will be held on November 3, 2026, to elect the thirty-eight U.S. representatives from the state of Texas, one from each of the state's thirty-eight congressional districts. The elections will coincide with other elections to the House of Representatives, elections to the United States Senate, and various state and local elections. The primary elections took place on March 3, 2026, and in races where no candidate receives over 50% in a primary, runoff elections took place on May 26.
== Unusual presentations of organizing pneumonia == While patchy bilateral disease is typical, there are unusual variants of organizing pneumonia where it may appear as multiple nodules or masses. One rare presentation, focal organizing pneumonia, may be indistinguishable from lung cancer based on imaging alone, requiring biopsy or surgical resection to make the diagnosis.
Therefore, the feedback that is read by this central regulator could include chemical and mechanical as well as cognitive cues. The significance of each of these factors will depend on the nature of the fatigue-inducing work that is being performed. Though not universally used, "metabolic fatigue" is a common alternative term for peripheral muscle weakness, because of the reduction in contractile force due to the direct or indirect effects of the reduction of substrates or accumulation of metabolites within the myocytes. This can occur through a simple lack of energy to fuel contraction, or through interference with the ability of Ca2+ to stimulate actin and myosin to contract.
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.